Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T14:57:28.292Z.
Calculation as of: 2026-10-06T14:57:28.292Z.
Quote observation: 2026-10-06T14:55:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 764f42141b21779aba3712b54ee9373bee46ed3fd4a49ef41b5b57d04fae8ed9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$244.00M
EV/FCF Ratio
N/A
TTM Avg
894.08x
3Y Avg
541.45x
5Y Avg
277.55x
Market Cap
$244.98M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$240.34M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$238.91M
EV/FCF Ratio
3.42x
TTM Avg
5.14x
3Y Avg
5.14x
5Y Avg
5.14x
Market Cap
$252.78M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Invivyd, Inc. (IVVD) | $244.52M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $244.00M | N/A | 894.08x | 541.45x | 277.55x |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $244.98M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $240.34M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $238.85M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $238.91M | 3.42x | 5.14x | 5.14x | 5.14x |
| High Tide Inc. (HITI)vs › | $237.69M | 25.46x | 23.33x | 20.20x | 22.09x |
| Galectin Therapeutics Inc. (GALT)vs › | $238.40M | N/A | N/A | N/A | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $252.78M | N/A | N/A | N/A | N/A |
| BioAge Labs Inc. (BIOA)vs › | $234.93M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
